LPCN
Lipocine Inc. · Healthcare
2.00
3.09%(+0.06)
Close2.00
0.00%(+0.00)
After HoursLast Updated: — ET
52W L: $1.8152W H: $12.37
$1.99
CHG-5.98 (-75.03%)
H$9.33
L$1.73
VOL5.4M
LPCN (1h)
Lipocine Inc. · Healthcare
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) CEO Mahesh Patel bought 25,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was bought at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the completion of the transaction, the chief executive officer directly owned 160,679
On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression (PPD).
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine's executive officers and whether investor losses may be recovered under federal securities laws.
Lipocine said LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 in the overall study population, and the primary endpoint was not met.
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the primary endpoint was not met In a post hoc analysis of participants (n=54) who had a history of psychiatric conditions, LPCN 1154 demonstrated nominal statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo as early as hour 12 and sustained through day 30 In the overall population, LPCN 1154 was well tolerated and demonstrated a differentiated safety profile with no reported adverse event, including somnolence or dizziness, occurring in more than 5% of the LPCN 1154-treated participants The Company plans to evaluate all available options going forward SALT LAKE CITY, April 2, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). For more information on the trial design, refer to clinicaltrials.gov: NCT06979544.
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the full year ended December 31, 2025 and provided a corporate update. "We believe 2025 was a pivotal year for Lipocine as we continue to advance our pipeline and expand our market presence.
Higuchi John W.
director
123,000 SH @ $2.05
2026-04-06
Patel Mahesh V.
director, officer: Chief Executive Officer
25,000 SH @ $2.03
2026-04-06
Patel Mahesh V.
director, officer: Chief Executive Officer
25,000 SH @ $2.02
2026-04-02
Patel Mahesh V.
director, officer: Chief Executive Officer
25,000 SH @ $8.00
2026-01-02
Patel Mahesh V.
director, officer: Chief Executive Officer
8,629 SH @ $4.20
2025-12-18
Fogarty Krista
officer: Principal Accounting Officer
20,786 SH @ $4.20
2025-12-18
Ono Richard Dana
director
1,764 SH @ $3.20
2025-06-04
Jene Jill M.
director
1,764 SH @ $3.20
2025-06-04